Scope Health

Scope Health is an international healthcare company specializing in ophthalmology, with a primary focus on the management of Ocular Surface Disease (OSD) and Age-Related Macular Degeneration (AMD). Founded in Ireland in 2009, the company has expanded significantly into the UK and US markets, offering a diverse portfolio of preservative-free eye drops, eyelid hygiene products, and nutritional supplements under brands such as OPTASE and HYLO. Scope Health is active in both the pharmaceutical and medical device sectors, providing innovative solutions like the BlephEx treatment for blepharitis and the recently acquired Eyetamins supplement line. The company also engages in research and development through partnerships, such as its collaboration with the Centre for Eye and Vision Research (CEVR) to develop next-generation ocular drug delivery technologies. Recently, the company has faced regulatory scrutiny, receiving an FDA warning letter in 2025 regarding the marketing of certain over-the-counter ophthalmic products.